查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606948

纖維肌痛藥物市場：按藥物類別、分銷管道分類 - 全球預測 2025-2030 年

Fibromyalgia Therapeutics Market by Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

纖維肌痛治療藥物市場2023年估值為34.7億美元，預計到2024年將達到36.7億美元，複合年成長率為5.07%，到2030年將達到49.1億美元。

纖維肌痛藥物包括旨在控制纖維肌痛症狀的治療，纖維肌痛是一種慢性疾病，其特徵是廣泛的肌肉骨骼疼痛，並伴隨疲勞、睡眠和情緒問題。這包括鎮痛藥、抗憂鬱症和抗驚厥藥等藥物治療，以及認知行為療法、運動計畫和替代療法等非藥物治療。對治療纖維肌痛的藥物的需求源於該疾病的流行及其對患者生活品質的影響，並且由於個體對治療的反應各不相同，因此強調個性化醫療方法。應用範圍從症狀緩解和功能增強到改善患者的心理健康。最終用途範圍主要是在醫療機構，例如醫院和疼痛管理專業中心，並且擴大採用在醫療監督下的家庭治療。

主要市場統計
基準年[2023] 34.7億美元
預計年份 [2024] 36.7億美元
預測年份 [2030] 49.1億美元
複合年成長率（%） 5.07%

根據市場洞察，纖維肌痛盛行率的上升以及對其治療性介入的認知的提高推動了這一成長。新型配方的開發和數位健康工具的整合（例如用於遠端患者管理的遠端醫療）提供了巨大的潛在機會。然而，市場面臨診斷複雜性、患者不遵守治療方法以及長期用藥帶來的副作用等挑戰。監管障礙和報銷問題進一步阻礙了成長。為了抓住新機遇，建議專注於以患者為中心的創新，例如個人化醫療和數位健康整合。此外，非侵入性治療方法的研究是技術進步和業務擴展的一個有前景的領域。

總體而言，纖維肌痛藥物市場需要持續創新，需要在製藥和技術公司之間進行大量研發投資以及合作，以提高治療效果和患者體驗。儘管面臨挑戰，這個市場對於相關人員尋求提供超越傳統治療的全面護理解決方案，並優先考慮適應性策略和患者參與舉措。有效的溝通和教育宣傳活動可以進一步促進醫療保健提供者和患者的市場滲透和接受度。

市場動態：揭示快速發展的纖維肌痛藥物市場的關鍵市場洞察

供需的動態交互作用正在改變纖維肌痛藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球纖維肌痛盛行率不斷上升
    • 確定纖維肌痛藥物的病因和有效性的臨床試驗數量增加
    • 傾向於疾病的早期診斷和早期治療
  • 市場限制因素
    • 纖維肌痛治療相關的高成本
  • 市場機會
    • 強調個人化醫療以進行有針對性和有效的纖維肌痛治療
    • 持續研究和開發有效的纖維肌痛治療藥物開發
  • 市場挑戰
    • 對纖維肌痛診斷不準確的擔憂

波特的五力：駕馭纖維肌痛藥市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對纖維肌痛藥物市場的影響

外部宏觀環境因素在塑造纖維肌痛治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解纖維肌痛治療藥物市場的競爭狀況

纖維肌痛治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣纖維肌痛藥物市場供應商的績效評估

FPNV 定位矩陣是評估纖維肌痛治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃纖維肌痛治療藥物市場的成功之路

對纖維肌痛治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 纖維肌痛症的盛行率在全球範圍內不斷增加
      • 增加確定纖維肌痛藥物的原因和有效性的臨床試驗
      • 疾病的早​​期診斷和治療趨勢
    • 抑制因素
      • 治療纖維肌痛的費用很高
    • 機會
      • 專注個人化醫療，針對性有效治療纖維肌痛
      • 持續研究和開發以開發纖維肌痛的有效治療方法
    • 任務
      • 與纖維肌痛診斷不準確有關的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的纖維肌痛治療藥物市場

  • 抗憂鬱症
  • 抗癲癇藥
  • 肌肉鬆弛劑

第7章纖維​​肌痛治療藥物市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章北美和南美纖維肌痛治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區纖維肌痛治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲纖維肌痛治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline（GSK）
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • Vertex Pharmaceuticals Incorporated
  • Viatris inc.
Product Code: MRR-8E22B61932B5

The Fibromyalgia Therapeutics Market was valued at USD 3.47 billion in 2023, expected to reach USD 3.67 billion in 2024, and is projected to grow at a CAGR of 5.07%, to USD 4.91 billion by 2030.

Fibromyalgia Therapeutics encompasses medical treatments aimed at managing the symptoms of fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, and mood issues. The scope includes pharmaceutical interventions, such as analgesics, antidepressants, and anticonvulsants, as well as non-pharmacological therapies like cognitive-behavioral therapy, physical exercise programs, and alternative remedies. The necessity for fibromyalgia therapeutics stems from the disorder's prevalence and its impact on patient quality of life, emphasizing personalized medicine approaches due to varied individual responses to treatments. Applications range from symptom relief and functional enhancement to improving patients' psychological well-being. The end-use scope primarily involves healthcare settings, such as hospitals and specialized pain-management centers, alongside increasing adoption of home-based therapies under medical guidance.

KEY MARKET STATISTICS
Base Year [2023] USD 3.47 billion
Estimated Year [2024] USD 3.67 billion
Forecast Year [2030] USD 4.91 billion
CAGR (%) 5.07%

Market insights reveal that growth is driven by the rising incidences of fibromyalgia and awareness about its therapeutic interventions. The development of novel drug formulations and the integration of digital health tools like telemedicine for remote patient management offer significant potential opportunities. However, the market faces challenges such as diagnosis complexities, patient non-adherence to treatment regimens, and side effects of chronic medication usage. Regulatory hurdles and reimbursement issues further inhibit growth. To capitalize on emerging opportunities, focusing on patient-centric innovations like personalized medicine and digital health integration is recommended. Additionally, research into non-invasive therapeutic modalities represents a promising area for technological advancement and business expansion.

Overall, the fibromyalgia therapeutics market demands continuous innovation, with substantial investment in R&D and collaboration between pharmaceutical companies and technology firms to enhance treatment efficacy and patient experience. Despite challenges, the market holds substantial promise for stakeholders who prioritize adaptive strategies and patient engagement initiatives, aiming to deliver comprehensive care solutions that transcend traditional therapeutic frameworks. Effective communication and education campaigns can further facilitate market penetration and acceptance among healthcare providers and patients alike.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fibromyalgia Therapeutics Market

The Fibromyalgia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of fibromyalgia worldwide
    • Rise in the number of clinical trials to determine causes and efficacy of fibromyalgia therapeutics
    • Inclination toward early diagnosis and treatment of diseases
  • Market Restraints
    • High cost associated with fibromyalgia treatment
  • Market Opportunities
    • Emphasis on personalized medicine for targeted and effective fibromyalgia therapies
    • Ongoing R&D for the development of efficient drugs for fibromyalgia
  • Market Challenges
    • Concerns associated with inaccurate diagnosis of fibromyalgia

Porter's Five Forces: A Strategic Tool for Navigating the Fibromyalgia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fibromyalgia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fibromyalgia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fibromyalgia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fibromyalgia Therapeutics Market

A detailed market share analysis in the Fibromyalgia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fibromyalgia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fibromyalgia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fibromyalgia Therapeutics Market

A strategic analysis of the Fibromyalgia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibromyalgia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Jazz Pharmaceuticals plc, Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, and Viatris inc..

Market Segmentation & Coverage

This research report categorizes the Fibromyalgia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antidepressants, Antiepileptic, and Muscle Relaxants.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of fibromyalgia worldwide
      • 5.1.1.2. Rise in the number of clinical trials to determine causes and efficacy of fibromyalgia therapeutics
      • 5.1.1.3. Inclination toward early diagnosis and treatment of diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with fibromyalgia treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emphasis on personalized medicine for targeted and effective fibromyalgia therapies
      • 5.1.3.2. Ongoing R&D for the development of efficient drugs for fibromyalgia
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with inaccurate diagnosis of fibromyalgia
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fibromyalgia Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antidepressants
  • 6.3. Antiepileptic
  • 6.4. Muscle Relaxants

7. Fibromyalgia Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Americas Fibromyalgia Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Fibromyalgia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Fibromyalgia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Amicus Therapeutics
  • 4. Astellas Pharma Inc
  • 5. AstraZeneca plc
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. BioMarin Pharmaceutical Inc
  • 9. C.H. Boehringer Sohn AG & Co. KG
  • 10. Eli Lilly and Company
  • 11. Gilead Sciences, Inc.
  • 12. GlaxoSmithKline (GSK)
  • 13. Jazz Pharmaceuticals plc
  • 14. Johnson & Johnson Services, Inc.
  • 15. Kyowa Kirin Co, Ltd
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer inc.
  • 19. Regeneron Pharmaceuticals, Inc.
  • 20. Roche Holding AG
  • 21. Sanofi S.A.
  • 22. Sarepta Therapeutics, Inc.
  • 23. Takeda Pharmaceutical Company
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. The Bristol-Myers Squibb Company
  • 26. Vertex Pharmaceuticals Incorporated
  • 27. Viatris inc.

LIST OF FIGURES

  • FIGURE 1. FIBROMYALGIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FIBROMYALGIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FIBROMYALGIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023